MorphoSys secures option to license Vivoryon’s QPCTL inhibitors for cancer

This article was originally published here

The option obtained by MorphoSys gives it the rights to globally develop and commercialise Vivoryon’s family of QPCTL inhibitors, including the latter’s lead compound PQ912. Currently, PQ912 had

The post MorphoSys secures option to license Vivoryon’s QPCTL inhibitors for cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply